Know More About “Active Pharmaceutical Ingredients CDMO Market 2021-2028” Growth Worldwide…Posted by Mrudula Anil Karmarkar on May 5th, 2023 The global active pharmaceutical ingredients CDMO market size is expected to reach USD 136.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.7% from 2021 to 2028. Increasing pharmaceutical R&D investment, patent expirations, and rise in demand for generic drugs and biologic innovation are the factors driving the market. The growth of small molecules, rising Active Pharmaceutical Ingredient (API) complexity, and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the Contract Development and Manufacturing Organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations. However, due to the COVID-19 pandemic, governments worldwide have opted to boycott APIs made in China. Due to government-imposed lockdown limitations in China, 44 firms were declared non-operational during the pandemic. As a consequence, various countries have launched programs to develop their own APIs, and countries across the EU have re-evaluated their healthcare models in order to combat the virus and ensure a steady supply of APIs. COVID-19 has placed unprecedented expectations on API makers, as evidenced by the substantial increase in demand for medications required to manage critically ill patients on mechanical ventilation. As a result, the sudden need to rapidly increase production has emphasized the need for adaptability for API CDMOs in maintaining drug supply, with some companies proving better able to withstand the pressures of quick scale up than others. The growth can be attributed to factors such as increased drug R&D, the rising incidence of chronic diseases, the expanding importance of generics, and the increasing consumption of biopharmaceuticals. To Request Sample Copy of this report, click the link: Pharma companies have been increasing the amount of discovery, development, and manufacturing work they outsource over the last couple of decades. However, the urge to outsource is not uniform in the biopharma industry. Small biotechnology companies frequently rely on a Contract Development and Manufacturing Organization (CDMO) to produce their development products as they go through the pipeline. COVID-19 has had a significant impact on the supply chain of the Active Pharmaceutical Ingredient (API), causing some level of disruption in terms of raw material supply and availability, shipping delays, and costs. As per the survey conducted by the Institute for Supply Management in February 2020, about 75.0% of responding companies experienced supply chain disruption as a result of COVID-19, and more than 44.0% did not have a plan to handle supply chain disturbance from China. Active Pharmaceutical Ingredients CDMO Market Report Highlights
CDMOs are proving to be extremely beneficial to the pharmaceutical and biotech industries since they provide prospective capabilities and cost savings over in-house manufacturing. There is a substantial link between corporate size and outsourcing in general. Small and medium-sized businesses (SMEs) have fewer stakeholders and organizational hurdles in the decision-making process, allowing for a more fluid decision-making process. Besides, more than 3,200 companies are currently engaged in active pharmaceutical ingredient manufacturing activities. As only one-third of these companies are linked with a corporate group that also has finished dose production capabilities, there is a lack of integration even though these are complementary businesses. List of Key Players of Active Pharmaceutical Ingredients CDMO Market
Like it? Share it! More by this author |